LUCID CAPITAL MARKETS Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $38
Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. ELOX | 0.00 |
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ:
ELOX) with a Buy rating and announces Price Target of $38.
